Inactive Instrument

News BioCardia Inc Nasdaq

Equities

US09060U1016

End-of-day quote Nasdaq Other stock markets
- ^USD	-

21/05	BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	MT
14/05	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	22/05	MT
BioCardia Announces Reverse Stock Split	22/05	AQ
Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024	15/05
BioCardia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	14/05	PU
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	09/05	AQ
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	01/05	AQ
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	01/05	CI
Transcript : BioCardia, Inc. - Special Call	01/05
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04	AQ
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04	CI
Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024	28/03
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	27/03	PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	20/03	AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	13/03	AQ
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	13/03	CI
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03	AQ
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03	CI
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioCardia Inc Nasdaq

Equities

US09060U1016

Summary

Filters